Table 4. Expected Hepatitis C complications in patients treated with DCV/ASV versus PR.
| DCV/ASV | PR | |||||||
|---|---|---|---|---|---|---|---|---|
| F4 (%) | DC (%) | HCC (%) | LT (%) | F4 (%) | DC (%) | HCC (%) | LT (%) | |
| % patients developing HCV complications | 1.90 | 2.85 | 1.54 | 0.34 | 17.75 | 26.59 | 14.39 | 3.20 |
| BCI 95% | 1.2–2.8 | 1.7–4.6 | 0.7–2.4 | 0.1–0.6 | 17–18.5 | 23.1–31.7 | 7.7–18.5 | 1.6–4.6 |
HCV: Hepatitis C Virus, PR: Peginterferon plus Ribavirin, PIs: Protease Inhibitors, DCV/ASV: Daclatasvir plus Asunaprevir, F4: cirrhosis, DC: Decompensated cirrhosis, HCC: hepatocellular carcinoma, HT: liver transplant, BCI: Bayesian credibility interval.